Medscheme released updated MEDICINE EXCLUSION LIST APRIL 2023

By HEOR Staff Writer

April 10, 2023

Some items listed as REQUIRING PRE-AUTHORISATION:

  • Forxiga (Dapagliflozin)
  • Byetta (Exenatide)
  • Janumet (Metformin/Sitagliptin)
  • Onglyza (Saxagliptin)
  • Januvia (Sitagliptin)
  • Galvus (Vildagliptin) + including Metformin combinations
  • Liptruzet (Atorvastatin/Ezetimibe)
  • Ezetrol (Ezetimibe)
  • Inegy(Ezetimibe/Simvastatin)

Details regarding the EXCLUDED ITEMS:

  • Trulicity (Dulaglutide)
  • Jardiance (Empagliflozin)
  • Xultophy (Insulin Degludec and Liraglutide)
  • Soliqua (Insulin Glargine and Lixisenatide)
  • Victoza (Liraglutide)
  • Synjardy (Metformin and Empagliflozin)
  • Ozempic (Semaglutide)
Reference url

Recent Posts

SAHPRA GMP Compliance: Addressing Allegations Against Adcock Ingram’s Clayville Facility

By HEOR Staff Writer

February 25, 2026

SAHPRA GMP compliance at Adcock Ingram's Clayville facility has been reaffirmed by the South African Health Products Regulatory Authority (SAHPRA) in its
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision

By João L. Carapinha

February 13, 2026

Exposing Prescription Drug Pricing Flaws Prescription drug pricing in the US is riddled with inefficiencies, as revealed in this JAMA interview published online on Febru...
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa

By João L. Carapinha

February 12, 2026

Pharmaceutical Tender Investigation Targets Ascendis, Pharma Q, and Sonke The Competition Commission of South Africa has launched a pharmaceutical tender investigation into manufacturers Ascendis, Pharma Q, and...